Maxim initiated coverage of Aytu BioPharma with a Buy rating and $5 price target. The company’s Adzenys XR-ODT and Cotempla XR-ODT for treating ADHD are seeing a tailwind of growth due to an ongoing shortage of stimulants, the analyst tells investors in a research note. Competitors are also having difficulties meeting demand, and this is a trend that does not seem to be ending any time soon, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AYTU:
